EBE announces the appointment of Michele Antonelli as Vice-President
Brussels, 14 May 2019 – The European Biopharmaceutical Enterprises (EBE) is pleased to announce the appointment of Mr Michele Antonelli, Chief Executive Officer of Stallergenes Greer, as EBE Vice-Pr...
Read moreHealth industries welcome unprecedented progress leading to an adoption of Horizon Europe, its areas for missions and partnerships
Brussels, 17 April 2019 The six undersigned European health industry associations representing small and large companies welcome the Council and the European Parliament agreement on the Horizon...
Read moreExit Strategies for SME Life Science Companies in the EU
When funding life science companies, investors need realistic expectations on how to recover their investment and, potentially, returns on their investment. A number of options exist, commonly c...
Read moreEBE Concept Paper – Management and Control of Raw Materials Used in the Manufacture of Biological Medicinal Products and ATMPs
Brussels, 17 December 2018 Effective management and control of raw materials (RM) used in the manufacture of biological medicinal products including advanced therapy medicinal products (ATMPs) requ...
Read moreHealth industries call for a rapid adoption of Horizon Europe, its missions and partnerships
Brussels, 26 November 2018 - Health industries call for a rapid adoption of Horizon Europe, its missions and partnerships The six undersigned European health industry associations are ambitious...
Read moreEBE-EFPIA Position Paper on Next Generation Sequencing (NGS)
Next generation sequencing (NGS), also known as high-throughput sequencing, is a DNA and RNA sequencing technology which has revolutionized genomic research. Today, an entire human genome can b...
Read moreJoint EBE-EFPIA Position on CE Marking
A Topic Group of the joint Personalised Medicine Working Group has been developing a slide deck highlighting the position of the pharmaceutical industry on the need to consider a risk-based a...
Read moreEBE View on the SPC Manufacturing Waiver
The European Biopharmaceutical Enterprises (EBE) has just released its latest position paper, raising concerns on how the SPC manufacturing waiver will affect innovative biopharmaceutical companies,...
Read moreNew EBE-EFPIA study demonstrates benefits of personalised medicine for patients, society and healthcare systems and makes recommendations for equitable access for patients in Europe
The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) released today the outcome of the evidence-based analysis on personal...
Read moreEBE announces its 2018-2020 Board of Directors
Brussels, 2 July 2018 – The European Biopharmaceutical Enterprises (EBE), is pleased to announce its Board of Directors for 2018-2020, following the decisions taken at the EBE Annual Meeting on 26 J...
Read more